Companies and investors are turning their attention to virtual reality technology, to enhance the impact and accessibility of mental health treatments.
It is hoped the digital solutions will eventually empower patients to self-administer psychedelic medicines, reducing the reliance on psychotherapists.
Read More
Senate-passed bill to decriminalise psychedelics advances through second reading.
Read More
The company is investigating DMT’s efficacy against treatment-resistant depression.
Read More
Tech startup Tripp to use virtual reality to improve psychedelic therapy.
Awakn Life Sciences to trial ketamine’s efficacy to treat gambling addictions.
Tryp Therapeutics completes psychotherapy training for Phase II clinical trial.
Bright Mind Biosciences’ proprietary compound advances pre-clinical trials.
Investors are tripping on psychedelics startups despite a murky path to commercial success.
Cybin files two patents to support research programmes.
Psycheceutical files patents for targeted drug delivery.
Ketamine One establishes medical advisory board.
All-inclusive magic mushroom retreats are the new luxury.
Ketamine for depression could help relieve some of the mental health burden caused by pandemic, experts say.
Mydecine signs research agreement with Johns Hopkins University.
The University of Wisconsin-Madison creates psychedelic research centre.
PharmaDrug partners with Johns Hopkins University for DMT clinical trials.
At-home genetic testing can’t tell you if you’re going to have a bad trip.
Study to determine if psychedelics help to quit cigarettes.
How can psychedelics be used to treat addiction?
Researchers work to integrate psychedelic drug and music therapies using technology.
Exploring research on psychedelics and autism.
Ketamine to be offered at UK’s first psychedelic-assisted therapy clinic.
Portland activists push to decriminalise psychedelics cultivation, gifting and community ceremonies.
People living with untreatable depression call on Saskatoon government to cover ketamine therapy.